Metraipolis › archive › dc_eaafad7cb9f1

Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism — Europe PMC PMID:35913960

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35913960
DOI
10.1371/journal.pone.0272380
License (as archived)
CC0-1.0
Archived
2026-10-17T07:05:21.641Z
SHA-256 of the archived text
e724d55947db3eb9d1c5ec2a3f2d7b43f82e22e3f35f03de207371bd4d3719bd
Stable URL of this page
https://metraipolis.com/documento/dc_eaafad7cb9f1

How to cite

Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism — Europe PMC PMID:35913960 — Europe PMC (en), https://europepmc.org/article/MED/35913960 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_eaafad7cb9f1 (Metraipolis archive dc_eaafad7cb9f1, sha256 e724d55947db3eb9d1c5ec2a3f2d7b43f82e22e3f35f03de207371bd4d3719bd)
BibTeX
@misc{dceaafad7cb9f1,
  title = {Chemical evidence for the tradeoff-in-the-nephron hypothesis to explain secondary hyperparathyroidism — Europe PMC PMID:35913960},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35913960},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_eaafad7cb9f1; sha256 e724d55947db3eb9d1c5ec2a3f2d7b43f82e22e3f35f03de207371bd4d3719bd},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35913960. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Secondary hyperparathyroidism (SHPT) complicates advanced chronic kidney disease (CKD) and causes skeletal and other morbidity. In animal models of CKD, SHPT was prevented and reversed by reduction of dietary phosphate in proportion to GFR, but the phenomena underlying these observations are not understood. The tradeoff-in-the-nephron hypothesis states that as GFR falls, the phosphate concentration in the distal convoluted tubule ([P]DCT]) rises, reduces the ionized calcium concentration in that segment ([Ca++]DCT), and thereby induces increased secretion of parathyroid hormone (PTH) to maintain normal calcium reabsorption. In patients with CKD, we previously documented correlations between [PTH] and phosphate excreted per volume of filtrate (EP/Ccr), a surrogate for [P]DCT. In the present investigation, we estimated [P]DCT from physiologic considerations and measurements of phosphaturia, and sought evidence for a specific chemical phenomenon by which increased [P]DCT could lower [Ca++]DCT and raise [PTH]. Methods and findings: We studied 28 patients ("CKD") with eGFR of 14-49 mL/min/1.73m2 (mean 29.9 ± 9.5) and 27 controls ("CTRL") with eGFR > 60 mL/min/1.73m2 (mean 86.2 ± 10.2). In each subject, total [Ca]DCT and [P]DCT were deduced from relevant laboratory data. The Joint Expert Speciation System (JESS) was used to calculate [Ca++]DCT and concentrations of related chemical species under the assumption that a solid phase of amorphous calcium phosphate (Ca3(PO4)2 (am., s.)) could precipitate. Regressions of [PTH] on eGFR, [P]DCT, and [Ca++]DCT were then examined. At filtrate pH of 6.8 and 7.0, [P]DCT was found to be the sole determinant of [Ca++]DCT, and precipitation of Ca3(PO4)2 (am., s.) appeared to mediate this result. At pH 6.6, total [Ca]DCT was the principal determinant of [Ca++]DCT, [P]DCT was a minor determinant, and precipitation of Ca3(PO4)2 (am., s.) was predicted in no CKD and five CTRL. In CKD, at all three pH values, [PTH] varied directly with [P]DCT and inversely with [Ca++]DCT, and a reduced [Ca++]DCT was identified at which [PTH] rose unequivocally. Relationships of [PTH] to [Ca++]DCT and to eGFR resembled each other closely. Conclusions: As [P]DCT increases, chemical speciation calculations predict reduction of [Ca++]DCT through precipitation of Ca3(PO4)2 (am., s.). [PTH] appears to rise unequivocally if [Ca++]DCT falls sufficiently. These results support the tradeoff-in-the-nephron hypothesis, and they explain why proportional phosphate restriction prevented and reversed SHPT in experimental CKD. Whether equally stringent treatment can be as efficacious in humans warrants investigation.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-08-01).
Identificativi: PMID 35913960 · PMCID PMC9342777 · DOI 10.1371/journal.pone.0272380.
Descrittori MeSH principali: Hyperparathyroidism, Secondary; Renal Insufficiency, Chronic.
Pagina: https://europepmc.org/article/MED/35913960 — https://doi.org/10.1371/journal.pone.0272380. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-17T06:51:36.552Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.